A study has suggested that a new drug formulation can be successful in treating two serious eye conditions.
Dr Matthew Benz, retinal surgeon at the Methodist Hospital in Houston, reported the findings of a phase III trial into the uses of microplasmin at the World Ophthalmology Congress in Berlin.
The trial, which involved 326 people and was carried out on behalf of biopharmaceutical firm ThromboGenics NV, found that 27.7 per cent of vitreomacular adhesion patients treated with microplasmin saw their problem corrected, compared to 13.2 per cent of those receiving a placebo.
In addition, another study showed that the drug had a 45.6 per cent with macular hole patents, while 15.6 per cent of the placebo group saw their condition alleviated.
Dr Benz commented: "The ability to cure a significant proportion of patients with a range of retinal disorders, including macular hole, with a simple injection of microplasmin is clearly an attractive alternative to the current option of surgery."
This follows recent research published in the Ophthalmology journal claimed that antidepressants can increase the risk of cataracts.
by Alexa Kaczka